SynthesisBMC women's health2025

Comparison of the efficacy and safety of docetaxel plus capecitabine versus docetaxel plus epirubicin for human epidermal growth factor 2 -negative breast cancer: a meta-analysis.

Jie Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.